StockNews.AI
ACAD
StockNews.AI
174 days

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

1. Acadia achieved record revenues in Q4 2024 and anticipates continued growth. 2. Investment in consumer activation is planned to support further market share expansion.

Earnings
+1.79%Current Return
VS
-1.6%S&P 500
$1902/26 04:34 PM EDTEvent Start
$19.3402/27 11:23 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Record revenue and growth projections indicate strong performance, similarly seen in past successful quarters.

How important is it?

Positive financial results and growth strategy indicate potential for significant price movement in ACAD.

Why Long Term?

Future growth strategies may benefit revenue over multiple quarters, warranting long-term investor confidence.

Related Companies

VRTXBIIBREGN
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025,” said Catherine Owen Adams, Chief Executive Officer. “To support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for NU.

Related News